The calcium-sensing receptor (CaSR) is a G protein-coupled receptor (GPCR) that signals through G q/11 and G i/o to stimulate cytosolic calcium (Ca 
INTRODUCTION
The calcium-sensing receptor (CaSR) is a family C heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) that is highly abundant in the parathyroid glands and kidneys and plays an essential role in extracellular calcium (Ca 2+ e ) homeostasis by decreasing parathyroid hormone (PTH) secretion and increasing urinary calcium excretion in response to increases in Ca 2+ e concentrations (1) . The human CaSR is encoded by the CASR gene located on chromosome 3q21.1 and consists of an extracellular domain, which binds Ca 2+ e and mediates receptor dimerization; seven transmembrane domains (TMDs); and an intracellular domain, which is involved in activation of downstream signaling effectors such as G proteins and phospholipase C (PLC) (2, 3) . The CaSR stimulates two major signal transduction cascades. The first is the G q/11 -PLC-mediated generation of inositol 1,4,5-trisphosphate (IP 3 ), which induces a rapid rise in intracellular calcium (Ca 2+ i ) concentrations (4) . The second is the mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), which phosphorylate proteins mediating cytosolic signaling and translocate into the nucleus to activate transcription factors involved in cellular proliferation and differentiation (5) . The CaSR has been shown to activate MAPK signaling in a manner that depends on the G proteins G q/11 , and G i/o , which inhibits cyclic adenosine monophosphate (cAMP) synthesis, and by a potentially G protein-independent mechanism involving -arrestin types 1 and 2 (6) . -Arrestins are intracellular scaffolding proteins that play a critical role in inactivating GPCRs by inhibiting interactions with G proteins and by targeting these receptors for clathrin-mediated endocytosis (7) . Moreover, -arrestins have been shown to enhance GPCR-mediated MAPK signaling from clathrincoated structures (8) .
The importance of the CaSR in the regulation of Ca 2+ e has been highlighted by the identification of loss-of-function CaSR mutations that give rise to familial hypocalciuric hypercalcemia type 1 (FHH1) and neonatal severe hyperparathyroidism, as well as by gain-of-function CaSR mutations that cause autosomal dominant hypocalcemia type 1 (ADH1), which is characterized by hypocalcemia, hyperphosphatemia, normal or low circulating PTH concentrations, ectopic calcifications, and a relative or absolute hypercalciuria (9, 10) . Functional studies have demonstrated that these disease-causing mutations may influence the signaling responses of CaSR-expressing cells in a biased manner (11) . Thus, some FHH1-causing mutations switch the CaSR from preferentially coupling to Ca and MAPK pathways or predominantly through MAPK (11) . In contrast, many ADH1-associated CaSR mutations lead to a signaling bias by causing CaSR to couple more strongly to Ca 2+ i (11) than to MAPK pathways. Studies involving positive and negative allosteric CaSRmodulating compounds, known as calcimimetics and calcilytics, respectively, have also revealed biased signaling responses, with both classes of drugs influencing Ca 2+ i to a greater extent than they do ERK1/2 phosphorylation (12) . Although these findings have established that agonist-induced CaSR signaling may occur in a biased
CaSR
R680G is present at the plasma membrane and does not exhibit abnormal intracellular calcium signaling FHH1-causing mutations at Arg 680 have been reported to decrease CaSR accumulation at the cell surface (11) . We therefore evaluated whether the ADH1-causing R680G mutation may also affect the abundance of CaSR at the plasma membrane. Western blot analyses, using cytoplasmic and plasma membrane fractions of human embryonic kidney (HEK) 293 cells transiently transfected with plasmid constructs that expressed either the wild-type (CaSR WT ) or mutant (CaSR R680G ) CaSR fused to the N terminus of enhanced green fluorescent protein (pEGFP-N1) (16, 17) , revealed both CaSR WT and CaSR R680G to be present at the cell surface ( fig. S1 , A to D). Furthermore, quantification of the abundance of CaSR WT and CaSR R680G at the plasma membrane by Western blot analyses of cells that transiently expressed each protein and were biotinylated using the membrane-impermeant sulfo-NHS-SS-biotin revealed that the abundance of CaSR WT and CaSR R680G at the cell surface was not significantly different (figs. S1 and S2, A to C). Thus, unlike the FHH-causing mutations at Arg 680 , the R680G mutation did not alter the abundance of the CaSR at the plasma membrane.
To assess the effects of the R680G mutation on CaSR-mediated Ca (Fig. 2, B and C) (Fig. 2, B and C) . In contrast, this concentration of NPS-2143 had no significant effect on the EC 50 values of cells expressing CaSR R680G (Fig. 2, B and C) . Thus, the R680G mutation abrogated the effect of NPS-2143 on CaSR-mediated Ca 2+ i responses. To verify the findings of the Ca 2+ i Fluo-4 assays, we performed luciferase reporter assays using a construct containing a nuclear factor of activated T cell (NFAT) response element, which is activated by increases in Ca 2+ i (20 ] e responses and presented as means ± SEM of four transfections. *P < 0.05, **P < 0.01, and ****P < 0.0001 using two-way analysis of variance (ANOVA) with . Western blot analysis confirmed the expression of wild-type and mutant CaSRs in these cells (Fig. 2D) , and the NFAT reporter activity increased in a dose-dependent manner after stimulation with increasing [Ca 2+ ] e (Fig. 2E) ] e using AlphaScreen analysis (Fig. 3 , C and D) after Western blotting to confirm the expression of wild-type and mutant CaSRs in the cells (Fig. 3C ). Ca 2+ e stimulation induced a dosedependent increase in phosphorylated ERK1/2 fold-change responses in all cells (Fig. 3D ). These responses were significantly increased at 10 mM [Ca 2+ ] e , a concentration that has been reported to lead to near-maximal signaling responses in CaSR-expressing HEK293 cells (21) , in both the CaSR (Fig. 3D) . We also investigated the effect of the R680G CaSR mutation on MAPK signaling by measuring gene transcription induced by a luciferase reporter construct containing a serum-response element (SRE), which is a downstream target of ERK1/2 signaling (21, 22) . Western blot analysis confirmed expression of wild-type and mutant CaSRs in cells used for the SRE reporter experiments (Fig. 3E) , and exposure to Ca 2+ e led to a dose-dependent increase in SRE reporter activity in all cell types (Fig. 3F) (Fig. 3F) . Thus, the R680G mutation increased MAPK signaling, consistent with this being a gain-of-function mutation (11) . To determine whether the CaSR R680G may interfere with the effect of NPS-2143 on CaSR-induced MAPK signaling, we repeated the SRE experiment in the presence of 500 nM NPS-2143 and after stimulation with 10 mM [Ca 2+ ] e . The presence of NPS-2143 did not alter expression of the wild-type or mutant CaSRs (Fig. 3G) (Fig. 4B) . The G q/11 pathway was evaluated further by assessing the effects of two inhibitors of the G q/11 pathway, YM-254890 and UBO-QIC, both of which selectively block guanosine diphosphate dissociation from G q (24, 25) , on SRE reporter activity in cells expressing wild-type or mutant CaSRs (Fig. 4C) 5 , B and C). To confirm that the R680G mutation does not enhance MAPK signaling through a G i/o -dependent pathway, we also evaluated SRE reporter activity in the presence of pertussis toxin (PTx), which is a selective G i/o inhibitor. Treatment with PTx or vehicle had no effect on the expression of CaSR WT , CaSR R680G , or CaSR L173F (Fig. 5D ). However, addition of PTx led to a similar (>50%) reduction in SRE reporter fold-change responses in both wild-type and mutant CaSR-expressing cells compared to the respective vehicle-treated cells (Fig. 5E ), although PTx-treated CaSR R680G -expressing cells continued to show significantly increased SRE reporter responses compared to PTx-treated cells expressing CaSR WT (Fig. 5F ). Thus, inhibition of G i/o -mediated signaling does not rectify the increased SRE reporter responses caused by the R680G mutation, and overall, the combined results indicate that the gain of function associated with the R680G mutation likely involves a mechanism that is independent of G q/11 and G i/o .
The increased MAPK responses of CaSR
R680G are mediated by -arrestin To determine whether the increased MAPK signaling responses of cells expressing CaSR R680G may be mediated by a -arrestin-dependent pathway, we performed SRE reporter assays in the presence of single small interfering RNAs (siRNAs) targeting either -arrestin1 or -arrestin2 or a scrambled siRNA sequence. Treatment of HEK293 cells transiently expressing CaSR CaSR expression (Fig. 6, A and B (Fig. 6, C and D) . Moreover, the knockdown of -arrestin1 or -arrestin2 in cells expressing CaSR R680G led to a marked reduction (>80%) in SRE reporter activity compared to the same cells treated with scrambled siRNA (Fig. 6, C and D) . However, the increase in SRE reporter activity of cells expressing CaSR L173F was not altered by knocking down -arrestin1 or -arrestin2 (Fig. 6, E and F -Glu 767 salt bridge that is required for -arrestin-mediated CaSR signaling To determine the mechanism by which the R680G mutation, which is located in TMD3 of CaSR (Fig. 7A) , may influence -arrestin-mediated signaling, we constructed a homology model of the TMDs and evaluated the structural consequences of the R680G mutation (Fig. 7, B to D) . Because a crystal structure of the TMD of the CaSR does not exist, we generated a homology model based on the crystal structure of the TMD of the related family C GPCR human metabotropic glutamate receptor 1 (mGluR1) (26) , which is likely to have a similar structural topology to the CaSR TMD. For the homology modeling, we used the mGluR1 TMD in complex with the negative allosteric modulator FITM [4- (Fig. 8, C and D) . Moreover, treatment with siRNAs targeting -arrestin1 or -arrestin2 had no effect on SRE responses in cells expressing CaSR E837R (Fig. 8, C and D In contrast, SRE reporter activity decreased significantly upon knockdown of -arrestin1 or -arrestin2 in cells expressing CaSR E767R in the presence of 2.5 to 10 mM Ca 2+ e , compared to the same cells treated with scrambled siRNA (Fig. 8, C and D) . These findings indicate that, similar to the R680G mutation, the E767R mutation significantly increased CaSRinduced MAPK signaling through a -arrestin-mediated pathway and that (Fig. 8,  G and H) . Thus, these doublemutant studies demonstrated the importance of the salt bridge between residues 680 and 767 for CaSR-induced MAPK signaling.
DISCUSSION
Our studies have identified a previously undescribed ADH1-causing mutation affecting the CaSR (R680G), which causes a biased signaling response to Ca (Figs. 2,  3, and 6 ). The effect of this mutation contrasts with most of the mutations associated with ADH1, which bias the CaSR toward Ca 2+ i signaling (11) . The CaSR is most abundant in the parathyroid glands (30) , and the demonstration that the R680G CaSR mutation leads to selective MAPK activation suggests that this signaling pathway may influence the parathyroid set point for PTH release. Thus, the hypocalcemia in the family harboring this CaSR mutation may have been caused by the MAPK pathway increasing the sensitivity of parathyroid cells to Ca 2+ e , which impaired the synthesis and release of PTH at physiological Ca 2+ e concentrations. Con sistent with this, an ex vivo study has previously shown alterations in MAPK activity to acutely influence PTH secretion from cultured human parathyroid cells (31) . However, the physiological significance of CaSR-mediated biased signaling leading to MAPK activation remains to be elucidated. Furthermore, our studies have revealed the importance of functionally characterizing CaSR variants by measuring both Ca as polymorphisms may require further evaluation to ensure that biased signaling is not a feature of these variants. Our studies also reveal that the Arg 680 residue is critical for the binding and efficacy of the allosteric CaSR modulator NPS-2143. Allosteric CaSR modulators such as NPS-2143 have been predicted to bind to a cavity formed by the extracellular portions of the CaSR TMDs (18) . The Arg 680 residue is located at the entrance to this putative binding cavity, and our results showing that the CaSR R680G mutation abolishes NPS-2143-mediated Ca
2+
i and MAPK responses demonstrate the importance of the CaSR Arg 680 residue in mediating the action of this calcilytic drug (18) .
The CaSR has previously been shown to activate the MAPK cascade through G q/11 and G i/o (5) , and in keeping with this, our analysis of the reported ADH1-causing L173F CaSR mutant showed this to enhance MAPK signaling through G q/11 and G i/o (Figs. 3 to 5) . Thus, two inhibitors of the G q/11 pathway, YM-254890 and UBO-QIC, and PTx, a selective inhibitor of G i/o , abolished and reduced, respectively, the enhanced MAPK signaling associated with the L173F mutant CaSR (Figs. 4 and 5) . In contrast, assessment of the newly identified ADH1-causing R680G mutant CaSR using the G q/11 and G i/o inhibitors revealed that the associated increased MAPK signaling remained significantly increased compared to the MAPK signaling in similarly treated cells expressing wild-type CaSR (Figs. 4 and 5) , although it was reduced when compared to untreated cells expressing the G680 CaSR mutant (Figs. 4 and 5) . However, the increased MAPK signaling due to the R680G mutation, but not that due to the L173F mutation, was significantly reduced by knockdown of -arrestin1 or -arrestin2 when compared to similarly treated cells expressing wild-type CaSR (Figs. 4 and 5) . Together, these results indicate that the gain-offunction L173F mutant CaSR signals through the canonical G q/11 and G i/o pathways, but the gain-of-function R680G mutant CaSR signals through the canonical pathways and a noncanonical pathway that is independent of G q/11 and G i/o and involves the -arrestin proteins (Fig. 6) .
The -arrestins may enhance ERK1/2 signaling by acting as protein scaffolds that mediate the association of ERK1/2 with upstream MAPK components such as Raf-1 and the MAPK and ERK kinases 1 and 2 (MEK1/2) (32). The assembly of the -arrestin-MAPK complex is triggered by GPCR activation and occurs after agonist-bound GPCRs have undergone clathrin-mediated endocytosis (33) . Thus, CaSR endocytosis is likely required to mediate -arrestin-dependent MAPK activation, and this is consistent with our reported finding of impaired CaSR-MAPK signaling due to FHH3-associated loss-of-function mutations of the adaptor-related protein 2 sigma subunit (AP2), which mediates the formation of clathrin-coated vesicles (21) . Moreover, our present study has revealed that -arrestin1 and -arrestin2 mediated the gain of function caused by the R680G CaSR mutation (Fig. 6) , and note that both of these -arrestin isoforms, which are present in the parathyroid glands, have been reported by coimmunoprecipitation and mammalian two-hybrid assays to directly bind to the CaSR cytoplasmic terminus (34) . The role of -arrestins in GPCR endocytosis and signal transduction has been characterized (7, 32) , although the GPCR domains and structural motifs that mediate these interactions with -arrestins have not been fully elucidated. A crystal structure analysis of the GPCR family A member  2 -adrenergic receptor ( 2 -AR) complexed with -arrestin1 has shown that the GPCR cytoplasmic terminus, third intracellular loop, and the inner membrane aspect of the TMDs facilitate -arrestin binding to the GPCR (35) . In addition, mutations affecting the cytoplasmic regions of family A and B GPCRs have been shown to selectively influence -arrestin-mediated signaling (36, 37) . Our finding that mutation of the CaSR Arg 680 residue, which is located at the outer end of TMD3 (Fig. 7) , also modulates -arrestin signaling reveals the importance of the extracellular regions of GPCRs for influencing -arrestin function. Our homology modeling and functional analysis of engineered CaSR mutants have revealed that the Arg 680 residue forms a salt bridge with the Glu 767 residue located in ECL2 (Fig. 8) and that this salt bridge likely maintains the CaSR in an inactive conformation. Disruption of this salt bridge by mutating either Arg 680 or Glu 767 led to a gain of function in -arrestinmediated MAPK signaling, whereas restoration of the salt bridge in the Glu 680 -Arg 767 double mutant normalized CaSR function (Fig. 8) . The Arg 680 -Glu 767 salt bridge therefore mediates a functionally important interaction between TMD3 and ECL2 (Figs. 7 and 8) . ECL2 connects the outer ends of TMD4 and TMD5 (Fig. 7, A and B) , and thus, it seems likely that disruption of the Arg 680 -Glu 767 salt bridge may lead to a lateral displacement of TMD3 away from TMD4 or TMD5, thereby facilitating -arrestin binding in a manner analogous to that reported in a cryo-electron microscopy structural analysis of the  2 -AR--arrestin complex, which showed that binding of -arrestin to the  2 -AR TMD domain core region is mediated by an outward shift in the positioning of the TMD3, TMD5, and TMD6 helices (35) .
In conclusion, we have identified a CaSR mutation (R680G) that gives rise to ADH1 by exclusively activating a -arrestin-mediated MAPK signaling pathway downstream of the CaSR. These studies provide key insights into CaSR structure and function and indicate that a salt bridge between TMD3 and ECL2 plays a critical role in the control of -arrestin-mediated CaSR signaling. Moreover, discovery of this novel -arrestin-specific pathway may help facilitate the development of targeted therapeutics that can activate CaSRmediated -arrestin signaling in a biased manner.
MATERIALS AND METHODS

DNA sequence analysis
Written informed consent was obtained from the individuals and their relatives, and where appropriate, the parents and guardians of children, using protocols approved by local and national ethics committees. Mutational analysis of the CASR exons and adjacent splice sites was performed as described (38) . Publicly accessible databases [Single Nucleotide Polymorphism Database (www.ncbi.nlm.nih.gov/ projects/SNP/) (39); 1000 Genomes (http://browser.1000genomes.org) (40); the NHLBI-ESP (http://evs.gs.washington.edu/EVS/, EVS data release ESP6500SI) with details from the exomes of about 6500 individuals; and ExAC (http://exac.broadinstitute.org/) with details from exomes of 60,706 unrelated individuals (41)] were examined for the presence of the c.2038C>G sequence variant.
Protein sequence analysis and alignment and three-dimensional modeling of the CaSR structure The effect of the R680G mutation was predicted using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) (13) and MutationTaster (www.mutationtaster.org/) (14) . Protein sequences of CaSR orthologs were aligned using Clustal Omega (www.ebi.ac.uk/Tools/msa/ clustalo/) (42) . The HHpred homology detection server (https://toolkit. tuebingen.mpg.de/#/tools/hhpred) was used to identify proteins in the Protein Data Bank with structural similarity to the CaSR and to perform amino acid sequence alignment (43) . The amino acid sequence identity between human mGluR1 (44) and the CaSR is 28% for 282 aligned amino acid residues. The CaSR sequence was threaded onto the mGluR1 template coordinates, and Modeller (https://toolkit. tuebingen.mpg.de/#/tools/modeller) was used to construct a homology model (45) . Figures were prepared using the PyMOL Molecular Graphics System (Schrodinger LLC).
Cell culture, transfection, and siRNA-mediated knockdown Studies were performed in HEK293 cells maintained in Dulbecco's modified Eagle's medium-GlutaMAX medium (Thermo Fisher Scientific) with 10% fetal bovine serum (Gibco) at 37°C and 5% CO 2 .
Mutations were introduced into the pEGFP-N1-CaSR WT construct by site-directed mutagenesis using the QuikChange Lightning kit (Agilent Technologies) and gene-specific primers (Sigma-Aldrich), as described (46, 47) . Engineered mutations were verified using dideoxynucleotide sequencing with the BigDye Terminator v3.1 Cycle Sequencing kit (Life Technologies) and an automated detection system (ABI3730 automated capillary sequencer, Applied Biosystems), as previously reported (48) . Wild-type and mutant CaSR pEGFP-N1 constructs and luciferase reporter constructs (pGL4.30-NFAT and pGL4.33-SRE, Promega) were transiently transfected into HEK293 cells using Lipofectamine 2000 (Life Technologies) 48 hours before the experiments, as described (49) . Single siRNAs targeting -arrestin1 (catalog no. 6218S, Cell Signaling Technology) or -arrestin2 (catalog no. sc-29208, Santa Cruz Biotechnology) or scrambled siRNA (catalog no. SR301839, OriGene) was transfected 24 hours before the experiments at a concentration of 100 nM. Successful transfection was confirmed by Western blot analysis, with the calnexin housekeeping protein being used as a loading control (46) . Primary antibodies recognizing the following proteins were used for Western blot analysis at a dilution of 1:1000: CaSR (ADD, ab19347, Abcam), calnexin (Ab2301, Millipore), phosphorylated ERK1/2 (9101L, Cell Signaling Technology), total ERK1/2 (4695S, clone 137F5, Cell Signaling Technology), plasma membrane calcium adenosine triphosphatase (PMCA1) (ab190355, Abcam), -arrestin1 (ab175266, Abcam), and -arrestin2 (H-9, sc-13140, Santa Cruz Biotechnology). The Western blots were visualized using an Immun-Star WesternC kit (Bio-Rad) on a Bio-Rad ChemiDoc XRS+ system (46) . For cell fractionation studies, cells were transfected with CaSR constructs, and 48 hours later, plasma membrane and cytoplasmic fractions were isolated using a plasma membrane extraction kit (catalog no. 65400, Abcam), as described (50) . Plasma membrane fractions were dissolved in 0.5% Triton X-100 in phosphatebuffered saline (PBS), and the cytoplasmic fraction was dissolved in the supplied homogenization buffer. Each fraction was resuspended in Laemmli buffer, and Western blot analysis was performed, as described (48) . Calnexin was used as a loading control for cytoplasmic fractions, and the PMCA1 protein was used as a loading control for plasma membrane fractions. For studies of phosphorylated proteins, cells were treated for 5 min with either 0 or 5 mM Ca 2+ e before lysis, and proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE). After transfer to polyvinylidene difluoride membranes, blots were preincubated (blocked) with 5% bovine serum albumin (BSA) in tris-buffered saline with Tween 20 (TBSt) (Sigma-Aldrich) before probing for phosphorylated ERK. Blots were stripped with Restore Plus Western Blot Stripping Buffer (Thermo Fisher Scientific) for 15 min and then blocked with nonfat dried milk powder (commercially available as Marvel) dissolved in TBSt and reprobed for total ERK. Densitometry was performed using ImageJ 1.30 software [National Institutes of Health (NIH)] and analyzed using GraphPad Prism software (GraphPad Software) and are expressed as means ± SEM. For studies involving NPS-2143 (ab145050, Abcam), cells were incubated either with dimethyl sulfoxide (DMSO; vehicle) or with 500 nM NPS-2143 in DMSO for 30 min before undertaking Fluo-4 Ca 2+ i experiments (18) and for 4 hours before undertaking luciferase reporter assay experiments (49) .
Surface biotinylation experiments
Biotinylation assays were performed by adapting previously published methods (51) . Briefly, HEK293 cells were grown in T75 flasks and transiently transfected with 8 g of wild-type or mutant CaSR constructs. Forty-eight hours later, cells were biotinylated using the membrane-impermeant sulfo-NHS-SS-biotin (2.5 mg/ml in PBS; Pierce) for 30 min on ice. Cells were then rinsed with ice-cold PBS plus 100 mM glycine and solubilized in cell lysis buffer [150 mM NaCl, 50 mM tris-HCl (pH 7.4), 1 mM EDTA, and 1% Triton X-100] supplemented with one tablet of cOmplete, EDTA-free protease inhibitor cocktail (Roche). Cells were lysed for 1 hour at 4°C and pelleted at 13,000g for 15 min, and biotinylated proteins were isolated by incubation with streptavidin-agarose beads (Pierce) overnight at 4°C on a rotating wheel. Precipitates were washed with lysis buffer, and biotinylated proteins were eluted from beads using Laemmli buffer. Biotinylated proteins were then resolved by SDS-PAGE and probed for CaSR, as described above. A 1:10 dilution of total protein was resolved alongside biotinylated proteins as a control. Specificity of surface biotinylation was confirmed by the absence of the intracellular calnexin in the biotinylated fraction but by the presence in the total protein fraction. Densitometry was performed using the ImageJ 1.30 software (NIH) and analyzed using the GraphPad Prism software and are expressed as means ± SEM. (18) . Briefly, HEK293 cells were plated in poly-l-lysine-treated black-walled 96-well plates (Corning) and transiently transfected with wild-type or mutant pEGFP-N1-CaSR constructs (1000 ng/ml). On the following day, cells were incubated in serum-free medium for 2 hours and then loaded with Fluo-4 dye according to the manufacturer's instructions (Invitrogen). Cells were loaded for 40 min at 37°C, and then, either a 20% aqueous solution of 2-hydoxypropyl--cyclodextrin (vehicle) or 500 nM NPS-2143 was added. Cells were then incubated for a further 20 min at 37°C (18) . Baseline measurements were made, and increasing doses of CaCl 2 (0 to 10 mM) were injected into each well using an automated system. Changes in Ca 2+ i were recorded on a PHERAstar instrument (BMG Labtech) at 37°C with an excitation filter of 485 nm and an emission filter of 520 nm. The peak mean fluorescence ratio of the transient response after each individual stimulus was measured using MARS data analysis software (BMG Labtech) and expressed as a normalized response. Nonlinear regression of concentration-response curves was performed with GraphPad Prism using the normalized response at each [Ca 2+ ] e for each separate experiment and used to determine the EC 50 (that is, [Ca 2+ ] e required for 50% of the maximal response). Assays were performed in four biological replicates for each of the expression constructs. Statistical analysis was performed using the F test (52, 53) .
Intracellular calcium measurements Ca
Luciferase reporter assays
Luciferase reporter assays were undertaken to measure SRE and NFAT responses. Cells were plated in 24-well plates and transiently transfected with the wild-type or mutant CaSR pEGFP-N1 constructs (100 ng/ml), luciferase construct (100 ng/ml; either pGL4-NFAT or pGL4-SRE), and pRL (10 ng/ml). At 48 hours after transfection, cells were incubated in serum-free medium overnight. Cells were then incubated in serum-free medium containing 0 to 10 mM CaCl 2 for 4 hours. For studies with PTx (catalog no. P7208, Sigma-Aldrich), cells were preincubated with 10 M forskolin (MP Biomedicals) overnight and then with PTx (300 ng/ml) or ethanol-diluent vehicle (SigmaAldrich) added with 0 to 10 mM CaCl 2 (54) . For studies with G q/11 inhibitors, cells were pretreated with 10 M YM-254890 or vehicle (DMSO) for 5 min or with 1 M UBO-QIC or vehicle (DMSO) for 2 hours. Cells were lysed and assays were performed using Dual-Glo Luciferase (Promega) on a Veritas luminometer (Promega), as previously described (48) . Luciferase/Renilla ratios are shown as fold changes relative to responses at basal CaCl 2 concentrations (0.1 mM). Area under the curve was calculated using GraphPad Prism and expressed as means ± SEM.
AlphaScreen assays
AlphaScreen assays to measure phosphorylated ERK1/2 and cAMP were performed in 48-well plates using cells transiently transfected with 100 ng of the wild-type or mutant CaSR pEGFP-N1 constructs 48 hours before performance of assays. For phosphorylated ERK1/2 studies, cells were incubated in serum-free medium for 12 hours before 5-min treatment with 0.1 to 10 mM CaCl 2 . Cells were then lysed in Surefire lysis buffer (PerkinElmer), and phosphorylated ERK1/2 and total ERK1/2 assays were performed as previously described (21) . For the cAMP assays, cells were treated with 10 M forskolin for 30 min before CaCl 2 treatment in stimulation buffer (1× Hanks' buffered saline solution, 0.1% BSA, 0.1% 3-isobutyl-1-methylxanthine, and 0.5 mM Hepes) plus 0.1 to 10 mM CaCl 2 . Cells were incubated for 15 min, then lysed in a Hepes-based solution [0.1% BSA, 0.3% Tween 20, and 5 mM Hepes (pH 7.4)], and incubated for 4 hours. The fluorescence signal in AlphaScreen assays was measured using the PHERAstar FS microplate reader (BMG Labtech) (48) . Nonlinear regression of concentration-response curves was performed with GraphPad Prism for the determination of IC 50 (that is, [Ca 2+ ] e required for 50% inhibition of the maximal response).
IP 1 assay
Assays were performed in 48-well plates, and cells were transiently transfected with 100 ng of the wild-type or mutant CaSR pEGFP-N1 constructs 48 hours before the performance of assays. At 24 hours before the experiments, cells were replated in a 384-well plate, and 12 hours later, the medium was changed to serum-free medium. IP-One homogeneous time-resolved fluorescence assays (Cisbio) were performed according to the manufacturer's instructions and as previously described (23) . Cells were incubated for 30 min with stimulation buffer containing a single dose of CaCl 2 (0.1 to 10 mM), followed by lysis in the manufacturer-supplied lysis buffer. Plates were read on a PHERAstar FS microplate reader 1 hour later (BMG Labtech).
Statistical analysis
A minimum of four independent biological replicates were used for all statistical comparisons. EC 50 and IC 50 values were analyzed using the F test, as reported (53) . All other data were analyzed by two-way analysis of variance with Tukey's multiple comparison test. Statistical analyses were undertaken using GraphPad Prism software, and a value of P < 0.05 was considered significant for all analyses.
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